Clinical trials
Attention Deficit Disorder with Hyperactivity trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
61 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 1 |
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 7 |
| 2009 | 3 |
| 2010 | 5 |
| 2011 | 7 |
| 2012 | 8 |
| 2013 | 1 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 50 |
| Unknown status | 7 |
| Recruiting | 2 |
| Terminated | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Shire | 10 |
| Eli Lilly and Company | 8 |
| Medice Arzneimittel Pütter GmbH & Co KG | 4 |
| University of Cologne | 4 |
| Boehringer Ingelheim | 2 |
| Janssen-Cilag International NV | 2 |
| Novartis | 2 |
| Novartis Pharmaceuticals | 2 |
| Prof. Huss | 2 |
| University Hospital Tuebingen | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Attention Deficit Disorder with Hyperactivity | 61 |
| Borderline Personality Disorder | 3 |
| Oppositional Defiant Disorder | 3 |
| Spasm | 3 |
| Anxiety Disorders | 2 |
| Mental Disorders | 2 |
| Attention Deficit and Disruptive Behavior Disorders | 1 |
| Color Vision Defects | 1 |
| Compulsive Personality Disorder | 1 |
| Depressive Disorder | 1 |
Trials
Showing 51 to 61 of 61. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.